Surgical resection of recurrent endometrial carcinoma Journal Article
| Authors: | Awtrey, C. S.; Cadungog, M. G.; Leitao, M. M.; Alektiar, K. M.; Aghajanian, C.; Hummer, A. J.; Barakat, R. R.; Chi, D. S. |
| Article Title: | Surgical resection of recurrent endometrial carcinoma |
| Abstract: | Objective: Chances of survival after the diagnosis of recurrent endometrial cancer are poor. Although total pelvic exenteration has been described as a treatment for a select subset of patients with recurrent endometrial cancer, the use of other surgical procedures in this setting has not been well described. The objective of this study was to review our experience with non-exenterative surgery for recurrent endometrial cancer. Methods: We reviewed the medical records of all patients who underwent non-exenterative surgery for recurrent endometrial cancer between 1/91 and 1/03. Survival was determined from the time of surgery for recurrence to last follow-up. Survival was estimated using Kaplan-Meier methods. Differences in survival were analyzed using the log-rank test. The Fisher's exact test was used to compare optimal versus suboptimal cytoreduction against possible predictive factors. Results: Twenty-seven patients were identified. Fifteen patients (56%) had disease limited to the retroperitoneum, 10 patients (37%) had intraperitoneal disease, and 2 patients (7%) had both intra- and retroperitoneal disease. Cytoreduction to ≤2 cm of residual disease was achieved in 18 patients (67%), while 9 patients (33%) had cytoreduction to residual disease >2 cm. There were no major perioperative complications or mortalities. The median hospital stay was 7 days (range, 1-18 days). Additional therapies included intraoperative radiation therapy in 9 patients (33%), radiation therapy in 12 patients (44%), and chemotherapy in 10 patients (37%). The median follow-up for the entire cohort was 24 months (range, 5-84 months). The median progression-free survival was 14 months (95% CI, 6-23), and the median disease-specific survival was 35 months (95% CI, 24-not reached). Size of residual disease was the only significant predictor for both progression-free and disease-specific survival. Patients with residual disease ≤2 cm had a median disease-specific survival of 43 months (95% CI, 35-not reached) compared with 10 months (95% CI, 7-29) for those with >2 cm residual (P = 0.01). Conclusions: Surgical resection for recurrent endometrial cancer may provide an opportunity for long-term survival in a select patient population. The only factor associated with improved long-term outcome was the size of residual disease remaining at the end of surgical resection. © 2006 Elsevier Inc. All rights reserved. |
| Keywords: | adult; cancer survival; clinical article; controlled study; aged; middle aged; survival rate; retrospective studies; recurrent cancer; follow up; endometrium carcinoma; endometrial neoplasms; neoplasm recurrence, local; risk factors; deep vein thrombosis; pneumonia; hospitalization; minimal residual disease; medical record; urinary tract infection; carcinoma; predictor variable; pleura effusion; surgical resection; kaplan meier method; psychosis; ileus; fisher exact test; wound dehiscence; intraoperative radiotherapy; log rank test; retroperitoneal disease; recurrent endometrial carcinoma; aorta injury |
| Journal Title: | Gynecologic Oncology |
| Volume: | 102 |
| Issue: | 3 |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2006-09-01 |
| Start Page: | 480 |
| End Page: | 488 |
| Language: | English |
| DOI: | 10.1016/j.ygyno.2006.01.007 |
| PUBMED: | 16490236 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 12" - "Export Date: 4 June 2012" - "CODEN: GYNOA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work